DEFA14A: Palisade Bio Corrects Outstanding Share Count for Special Meeting

Palisade Bio, Inc. filed a supplement to its proxy statement, correcting the number of outstanding common shares for its upcoming Special Meeting due to recent warrant exercises.

Summary

• A supplement to the Definitive Proxy Statement, originally filed on October 28, 2025, has been issued.
• The supplement corrects an inadvertent error regarding the number of common stock shares reported as outstanding on the Record Date, October 17, 2025.
• The previously reported 139,564,572 shares outstanding is corrected to 148,964,572 shares outstanding.
• This correction is attributed to the exercise of 9,400,000 pre-funded warrants on the Record Date.
• The quorum requirement for the Special Meeting is consequently updated from 46,521,524 shares to 49,654,858 shares.
• The number of shares issuable upon exercise of warrants and pre-funded warrants is reduced from 83,883,928 to 74,483,928.
• Total shares of common stock issuable are now 101,545,343, down from 110,945,343.
• The company currently has less than 10.5% of its total authorized 280,000,000 shares of common stock available for future issuance.

Sentiment

Score: 5

Explanation: The filing is a factual correction of an administrative error regarding outstanding share count, which is neutral in sentiment. While the underlying warrant exercise increased dilution, the correction itself is a positive for transparency.

Positives

• The company is proactively correcting an administrative error, enhancing transparency and accuracy of its disclosures.
• The exercise of pre-funded warrants means those specific warrants are no longer a source of future dilution, as they have already been converted to common stock.

Negatives

• The corrected outstanding share count of 148,964,572 is higher than previously reported, indicating greater dilution than initially disclosed.
• A higher quorum of 49,654,858 shares is now required for the Special Meeting, potentially making it slightly more challenging to achieve.

Future Outlook

The filing does not provide new forward-looking statements or guidance beyond the administrative details of the Special Meeting.

Industry Context

This administrative correction of outstanding shares does not directly relate to broader industry trends or competitors. It is an internal corporate governance matter.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides accurate information regarding the number of outstanding shares and the quorum required for the Special Meeting, which is crucial for voting rights and meeting validity. The higher outstanding share count implies slightly greater dilution than previously reported.

Next Steps

• Stockholders are encouraged to read the original Proxy Statement and this Supplement in conjunction.
• The Special Meeting of Stockholders will be held virtually on December 3, 2025, at 9:00 a.m. Pacific Time.

Key Dates

Keywords

Palisade Bio, PALI, Proxy Statement, Shares Outstanding, Warrants, Special Meeting, Corporate Governance, SEC Filing, Share Count Correction